GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Allowance For Loans And Lease Losses

Omeros (FRA:3O8) Allowance For Loans And Lease Losses


View and export this data going back to 2009. Start your Free Trial

What is Omeros Allowance For Loans And Lease Losses?

Allowance For Loans And Lease Losses only applies to banks.


Omeros Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Allowance For Loans And Lease Losses
Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.